Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patient...(ary arteriesthe blood vessels that carry...)

Additional Data

A poster titled "Modification of the Eculizumab Dose to Successfully Manage Intravascular Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria" was presented yesterday at the ASH annual meeting by Richard Kelly, M.D., of St. James's University Hospital, Leeds, United Kingdom. The authors concluded that two alternative-dosing regimens of Soliris were well tolerated and could be employed in the small percentage of patients with PNH in whom complement inhibition is not consistently maintained using the standard dose. For details, visit: http://ash.confex.com/ash/2008/webprogram/Paper8331.html.

A poster titled "Reducing Intravascular Hemolysis on Ferritin Homeostasis in Eculizumab Treated Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients" was presented yesterday at the ASH annual meeting by Alexander Roeth, M.D. of the Department of Hematology, University Hospital Essen in Essen, Germany. The authors concluded that eculizumab was safe and well tolerated in the study patients, and that iron parameters in PNH patients treated with eculizumab should be monitored to determine if iron supplementation should be altered or iron depletion therapy should be considered. For details, visit: http://ash.confex.com/ash/2008/webprogram/Paper11166.html.

About PNH

PNH is a rare blood disorder that affects an estimated 8,000 to 10,000 people in North America and Europe and, using similar prevalence estimates, potentially 1,000 - 2,000 patients in Japan. (3) PNH strikes people of al
'/>"/>